Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment

B. Kay Young, Richard Camicioli, Linda Ganzini

    Research output: Contribution to journalArticle

    56 Citations (Scopus)

    Abstract

    Parkinson's disease (PD) is a progressive neurological condition that causes considerable disability in the elderly. Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium. Aged patients and those with dementia are particularly vulnerable to these adverse effects. Evaluating PD patients with drug induced neuropsychiatric adverse effects is made difficult by their complex clinical presentations. The treatment of drug-induced psychosis and delirium begins with manipulating the antiparkinsonian drug regimen, but this frequently worsens motor function. Atypical antipsychotics such as clozapine have been successfully employed to treat the psychosis without worsening the motor disability. Patient intolerance of clozapine therapy has prompted open-label studies with newer agents such as risperidone, remoxipride, zotepine, mianserin and ondansetron.

    Original languageEnglish (US)
    Pages (from-to)367-383
    Number of pages17
    JournalDrugs and Aging
    Volume10
    Issue number5
    StatePublished - 1997

    Fingerprint

    Antiparkinson Agents
    Parkinson Disease
    Delirium
    Clozapine
    Psychotic Disorders
    Remoxipride
    Substance-Induced Psychoses
    Pharmaceutical Preparations
    Mianserin
    Ondansetron
    Risperidone
    Levodopa
    Antipsychotic Agents
    Dementia
    Therapeutics

    ASJC Scopus subject areas

    • Pharmacology
    • Geriatrics and Gerontology

    Cite this

    Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. / Young, B. Kay; Camicioli, Richard; Ganzini, Linda.

    In: Drugs and Aging, Vol. 10, No. 5, 1997, p. 367-383.

    Research output: Contribution to journalArticle

    @article{8b2c436d49b6400595feb07ceff0b748,
    title = "Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment",
    abstract = "Parkinson's disease (PD) is a progressive neurological condition that causes considerable disability in the elderly. Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium. Aged patients and those with dementia are particularly vulnerable to these adverse effects. Evaluating PD patients with drug induced neuropsychiatric adverse effects is made difficult by their complex clinical presentations. The treatment of drug-induced psychosis and delirium begins with manipulating the antiparkinsonian drug regimen, but this frequently worsens motor function. Atypical antipsychotics such as clozapine have been successfully employed to treat the psychosis without worsening the motor disability. Patient intolerance of clozapine therapy has prompted open-label studies with newer agents such as risperidone, remoxipride, zotepine, mianserin and ondansetron.",
    author = "Young, {B. Kay} and Richard Camicioli and Linda Ganzini",
    year = "1997",
    language = "English (US)",
    volume = "10",
    pages = "367--383",
    journal = "Drugs and Aging",
    issn = "1170-229X",
    publisher = "Adis International Ltd",
    number = "5",

    }

    TY - JOUR

    T1 - Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment

    AU - Young, B. Kay

    AU - Camicioli, Richard

    AU - Ganzini, Linda

    PY - 1997

    Y1 - 1997

    N2 - Parkinson's disease (PD) is a progressive neurological condition that causes considerable disability in the elderly. Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium. Aged patients and those with dementia are particularly vulnerable to these adverse effects. Evaluating PD patients with drug induced neuropsychiatric adverse effects is made difficult by their complex clinical presentations. The treatment of drug-induced psychosis and delirium begins with manipulating the antiparkinsonian drug regimen, but this frequently worsens motor function. Atypical antipsychotics such as clozapine have been successfully employed to treat the psychosis without worsening the motor disability. Patient intolerance of clozapine therapy has prompted open-label studies with newer agents such as risperidone, remoxipride, zotepine, mianserin and ondansetron.

    AB - Parkinson's disease (PD) is a progressive neurological condition that causes considerable disability in the elderly. Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium. Aged patients and those with dementia are particularly vulnerable to these adverse effects. Evaluating PD patients with drug induced neuropsychiatric adverse effects is made difficult by their complex clinical presentations. The treatment of drug-induced psychosis and delirium begins with manipulating the antiparkinsonian drug regimen, but this frequently worsens motor function. Atypical antipsychotics such as clozapine have been successfully employed to treat the psychosis without worsening the motor disability. Patient intolerance of clozapine therapy has prompted open-label studies with newer agents such as risperidone, remoxipride, zotepine, mianserin and ondansetron.

    UR - http://www.scopus.com/inward/record.url?scp=0030983603&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0030983603&partnerID=8YFLogxK

    M3 - Article

    C2 - 9143857

    AN - SCOPUS:0030983603

    VL - 10

    SP - 367

    EP - 383

    JO - Drugs and Aging

    JF - Drugs and Aging

    SN - 1170-229X

    IS - 5

    ER -